Corpus Christi's obesity rate against Texas, Texas Medicaid's obesity non-coverage, an exhaustive local price search that found nothing, and Nueces County's provider ratio.
Corpus Christi's adult obesity rate is 39.7% (crude prevalence, BRFSS 2023, CDC PLACES) 1, 5.3 points above the Texas rate of 34.4% in that same 2023 cycle, and still hotter than the newest available state figure, 35.6% (Texas BRFSS 2024, cited for currency) 2.
The city has 317,419 residents inside a 448,012-person metro, with a median household income of $66,967 and 17.4% uninsured 345. Not one clinic here publishes what a GLP-1 costs.
Texas Medicaid does not cover GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) for weight-loss or obesity treatment. Texas is one of seven states that report covering no GLP-1 for obesity, per KFF's "Medicaid Coverage of and Spending on GLP-1s" (Elizabeth Williams, Jan 16, 2026) 8. Coverage for the same drugs prescribed for type 2 diabetes is required nationally under federal Medicaid rules: the distinction is the indication, not the drug. This is a state Medicaid policy fact, not an Astra coverage claim.
Texas's own vendor drug program formulary (txvendordrug.com) returned HTTP 403 to automated fetch on 2026-08-28 (Akamai block, multiple paths and user agents tried) and could not be directly verified, so brand-specific Texas preferred-drug-list placement and prior-authorization criteria for the diabetes-indicated products remain an open gap and are not published here.
The local-market finding is an absence, and it is the finding. An extensive check on 2026-08-28, covering the Medi-Weightloss and Genesis Lifestyle Medicine chain locators, the Better Business Bureau's Corpus Christi-area listings 9, a chamber-of-commerce directory, OpenStreetMap-tagged healthcare and wellness businesses across the city, and CHRISTUS Spohn's own site, found no Corpus Christi clinic publishing a self-pay GLP-1 price on its own website.
That is not the same as no clinics existing. It means a Corpus Christi resident cannot compare prices without booking consultations first, and no number here is papered over with a guess.
Astra's national price is $68/month for semaglutide and $118/month for tirzepatide, both 12-month plans billed annually at $816 and $1,416, the same price in every city and at every dose.
Corpus Christi and Nueces County hold three currently-Designated HRSA Primary Care HPSAs: two facility-based centers inside the city, Coastal Bend Wellness Foundation, Inc. (score 12, designated population 128,159, designated 8/1/2015) and Amistad Community Health Center, Incorporated (score 14, designated population 98,044, designated 9/1/2007), plus a county-wide Low-Income Population HPSA, "LI-Nueces County" (score 12, designated population 126,096, designated 12/31/2018), with a population-to-primary-care-provider ratio of 3,503:1 against HRSA's 3,000:1 adequacy goal, a shortfall of roughly 6.03 FTE providers. Six Mental Health HPSAs (scores 15-20) are also active over the same area (HRSA bulk data, pulled 2026-08-28) 67.
HRSA publishes no endocrinology- or obesity-medicine-specific shortage designation, so that ratio is the sourced proxy. Most GLP-1 prescribing starts in primary care rather than endocrinology, which makes this documented shortage the direct bottleneck Corpus Christi patients hit before ever reaching a specialist. No independently verified count of practicing endocrinologists or obesity-medicine physicians in the city was available this pass, and none is claimed 67.
Telehealth answers that bottleneck concretely: a licensed clinician online instead of waiting on a scarce local primary-care slot. See the Texas GLP-1 overview for statewide context.
Astra treats patients in Texas through state-licensed physicians.
Astra's pricing is the same nationwide, including in Corpus Christi: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans billed annually ($816 and $1,416 per year). Astra does not set city-specific prices.
Not that we could find. We checked national weight-loss chain locators (Medi-Weightloss, Genesis Lifestyle Medicine), the Better Business Bureau's Corpus Christi-area listings, a chamber-of-commerce directory, and mapped healthcare/wellness businesses across the city — as of August 2026, no Corpus Christi clinic publishes a self-pay GLP-1 price on its own website. That opacity is worth knowing before you go looking for a local quote.
We can't make a direct local price comparison, because no Corpus Christi clinic publishes its GLP-1 pricing (see above). What we can say plainly: Astra's price is fixed and public everywhere, including here — $68/month for semaglutide or $118/month for tirzepatide on a 12-month plan, no local markup. If you find a Corpus Christi clinic with a published price, compare it directly against those numbers.
No. Texas is one of seven states that report covering no GLP-1 medication for obesity/weight-loss treatment under Medicaid, per a January 2026 KFF analysis. Coverage for these same drugs when prescribed for type 2 diabetes is required nationally under federal Medicaid rules — the difference is the indication, not the drug.
It can be. Nueces County carries a federally designated primary care shortage: HRSA's county-wide Low-Income Population HPSA shows a population-to-primary-care-provider ratio of 3,503:1, against HRSA's goal of 3,000:1 — a shortfall of roughly 6 full-time providers. Two HRSA-designated health centers inside the city (Coastal Bend Wellness Foundation and Amistad Community Health Center) sit on top of the same underlying shortage. Since most GLP-1 prescriptions start in primary care, that shortage is a real barrier before a patient even gets to discuss treatment options.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.